Literature DB >> 12363406

Radioligand binding studies reveal agmatine is a more selective antagonist for a polyamine-site on the NMDA receptor than arcaine or ifenprodil.

D Alex Gibson1, Barton R Harris, D Trent Rogers, John M Littleton.   

Abstract

Ifenprodil, arcaine and agmatine have all been reported to inhibit the NMDA receptor by actions at polyamine-sites, however the specific sites with which these compounds interact is unknown. Here we used radioligand binding of [3H]MK-801 to a membrane preparation from rat cerebral cortex to investigate the interactions of these compounds with the NMDA receptor complex. In the absence of exogenous polyamines, agmatine reduced [3H]MK-801 binding only at concentrations over 500 micro M, as opposed to the putative polyamine-site antagonists arcaine and ifenprodil which directly reduce ligand binding at much lower concentrations (5 micro M) in the absence of polyamines. In our studies, all three compounds significantly reduced spermidine-potentiated [3H]MK-801 binding, however agmatine was the only compound effective at concentrations below those that produced direct inhibition of [3H]MK-801 binding. Under these conditions, agmatine had a K(i)=14.8 micro M for spermidine-potentiated [3H]MK-801 binding and displayed characteristics of a competitive antagonist. Agmatine, as well as ifenprodil and arcaine, also displaced [3H]spermidine from rat cortical membranes at concentrations similar to those that were effective at reducing spermidine-potentiated [3H]MK-801 binding. In conclusion, these data suggest that agmatine reduces the potentiating effects of polyamines by competitive antagonism at a specific site on the NMDA receptor complex, and that these actions of agmatine differ from those of ifenprodil and arcaine.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12363406     DOI: 10.1016/s0006-8993(02)03198-0

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  8 in total

Review 1.  Suicide and the polyamine system.

Authors:  Jeffrey A Gross; Gustavo Turecki
Journal:  CNS Neurol Disord Drug Targets       Date:  2013-11       Impact factor: 4.388

Review 2.  Agmatine: biological role and therapeutic potentials in morphine analgesia and dependence.

Authors:  Soundar Regunathan
Journal:  AAPS J       Date:  2006-07-21       Impact factor: 4.009

3.  Nitric oxide is involved in the memory facilitation induced by spermidine in rats.

Authors:  Gustavo Petri Guerra; Carlos Fernando Mello; Patricia Dutra Sauzem; Daiane Bolzan Berlese; Ana Flávia Furian; Zuleica Tabarelli; Maribel Antonello Rubin
Journal:  Psychopharmacology (Berl)       Date:  2006-04-07       Impact factor: 4.530

4.  Agmatine reduces balance deficits in a rat model of third trimester binge-like ethanol exposure.

Authors:  B Lewis; K A Wellmann; S Barron
Journal:  Pharmacol Biochem Behav       Date:  2007-07-25       Impact factor: 3.533

5.  Agmatine reduces ultrasonic vocalization deficits in female rat pups exposed neonatally to ethanol.

Authors:  Kristen Wellmann; Ben Lewis; Susan Barron
Journal:  Neurotoxicol Teratol       Date:  2009-11-27       Impact factor: 3.763

6.  Agmatine enhances the anticonvulsant action of phenobarbital and valproate in the mouse maximal electroshock seizure model.

Authors:  Jarogniew J Luszczki; Remigiusz Czernecki; Katarzyna Wojtal; Kinga K Borowicz; Stanislaw J Czuczwar
Journal:  J Neural Transm (Vienna)       Date:  2008-04-01       Impact factor: 3.575

7.  Immunoneutralization of agmatine sensitizes mice to micro-opioid receptor tolerance.

Authors:  Carrie L Wade; Lori L Eskridge; H Oanh X Nguyen; Kelley F Kitto; Laura S Stone; George Wilcox; Carolyn A Fairbanks
Journal:  J Pharmacol Exp Ther       Date:  2009-08-14       Impact factor: 4.030

8.  Agmatine requires GluN2B-containing NMDA receptors to inhibit the development of neuropathic pain.

Authors:  Cristina D Peterson; Kelley F Kitto; Harsha Verma; Kelsey Pflepsen; Eric Delpire; George L Wilcox; Carolyn A Fairbanks
Journal:  Mol Pain       Date:  2021 Jan-Dec       Impact factor: 3.395

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.